TY - JOUR AU - 이민형 DA - 2017/12 PY - 2017 UR - https://www.sciencedirect.com/science/article/pii/S0168365917308179?via%3Dihub UR - https://repository.hanyang.ac.kr/handle/20.500.11754/116576 AB - The number of people suffering from insulin-independent type 2 diabetes mellitus (T2DM) is ever increasing on a yearly basis. Current anti-diabetic medications often result in adverse weight gain and hypoglycemic episodes. Hypoglycemia can be avoided with glucagon-like peptide (GLP)-1 receptor agonists, which are expensive and require daily injections that may result immune activation. This study demonstrates the use of non-viral vector based oral delivery of GLP-1 gene through enterohepatic recycling pathways of bile acids. Oral administration of the plasmid DNA (pDNA) encoding GLP-1 decreased diabetic glucose levels to the normoglycemic range with significant weight reduction in a high-fat diet (HFD) induced diabetic mouse model and a genetically engineered T2DM rat model. This novel oral GLP1 delivery system is an attractive alternative to treat late-stage T2DM conditions that require repeated insulin injection and can potentially minimize the occurrence of hypoglycemic anomalies. PB - ELSEVIER SCIENCE BV KW - Diabetes KW - Peptide nanoparticle KW - Oral delivery KW - Hypoglycemia KW - Anti-obesity TI - Oral delivery of a therapeutic gene encoding glucagon-like peptide 1 to treat high fat diet-induced diabetes VL - 268 DO - 10.1016/j.jconrel.2017.08.035 T2 - JOURNAL OF CONTROLLED RELEASE ER -